Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease.

Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O'Donnell R, Tam J, Han Y, Colucci J, Giroux A, Zhu Y, Boucher M, Pikounis B, Xanthoudakis S, Roy S, Rigby M, Zamboni R, Robertson GS, Ng GY, Nicholson DW, Flückiger JP.

Br J Pharmacol. 2004 Feb;141(4):689-97. Epub 2004 Jan 26.

PMID:
14744804
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury.

Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, Giroux A, Robertson GS, Zamboni R, Nicholson DW, Holtzman DM.

J Biol Chem. 2002 Aug 16;277(33):30128-36. Epub 2002 Jun 10.

PMID:
12058036
[PubMed - indexed for MEDLINE]
Free Article
3.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

PMID:
11520890
[PubMed - indexed for MEDLINE]
4.

Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation.

Ferger B, Eberhardt O, Teismann P, de Groote C, Schulz JB.

J Neurochem. 1999 Sep;73(3):1329-32.

PMID:
10461928
[PubMed - indexed for MEDLINE]
5.

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J.

Glia. 2009 Aug 15;57(11):1154-67. doi: 10.1002/glia.20838.

PMID:
19115380
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia.

Schulz JB, Weller M, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, von Coelln R, Wüllner U, Löschmann PA, Beal MF, Dichgans J, Klockgether T.

Cell Death Differ. 1998 Oct;5(10):847-57.

PMID:
10203688
[PubMed - indexed for MEDLINE]
Free Article
7.

Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.

Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM.

Neuroscience. 2001;106(3):603-12.

PMID:
11591460
[PubMed - indexed for MEDLINE]
8.

Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate.

Greene JG, Greenamyre JT.

J Neurochem. 1995 Jan;64(1):430-6.

PMID:
7528265
[PubMed - indexed for MEDLINE]
9.

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.

Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M, Sagredo O, Di Marzo V, Fernández-Ruiz J.

Cell Death Dis. 2013 Oct 17;4:e862. doi: 10.1038/cddis.2013.387.

PMID:
24136226
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.

Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fernández-Ruiz J.

Neuroreport. 2003 May 6;14(6):813-6.

PMID:
12858038
[PubMed - indexed for MEDLINE]
11.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

PMID:
22860209
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.

Zeevalk GD, Manzino L, Sonsalla PK.

Exp Neurol. 2000 Feb;161(2):638-46.

PMID:
10686083
[PubMed - indexed for MEDLINE]
13.

A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo.

Yang L, Sugama S, Mischak RP, Kiaei M, Bizat N, Brouillet E, Joh TH, Beal MF.

Neurobiol Dis. 2004 Nov;17(2):250-9.

PMID:
15474362
[PubMed - indexed for MEDLINE]
14.

Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.

Bizat N, Hermel JM, Boyer F, Jacquard C, Créminon C, Ouary S, Escartin C, Hantraye P, Kajewski S, Brouillet E.

J Neurosci. 2003 Jun 15;23(12):5020-30. Erratum in: J Neurosci. 2003 Oct 29;23(30):9960.

PMID:
12832525
[PubMed - indexed for MEDLINE]
Free Article
15.

Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment.

Levivier M, Przedborski S.

Neurol Res. 1998 Jan;20(1):46-56.

PMID:
9471103
[PubMed - indexed for MEDLINE]
16.

Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pèzzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M.

J Neurosci. 2002 Mar 1;22(5):1967-75.

PMID:
11880527
[PubMed - indexed for MEDLINE]
Free Article
17.

Protection of malonate-induced GABA but not dopamine loss by GABA transporter blockade in rat striatum.

Zeevalk GD, Manzino L, Sonsalla PK.

Exp Neurol. 2002 Jul;176(1):193-202.

PMID:
12093096
[PubMed - indexed for MEDLINE]
18.

Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.

Xia XG, Schmidt N, Teismann P, Ferger B, Schulz JB.

J Neurochem. 2001 Oct;79(1):63-70.

PMID:
11595758
[PubMed - indexed for MEDLINE]
19.

UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.

de Lago E, Fernández-Ruiz J, Ortega-Gutiérrez S, Cabranes A, Pryce G, Baker D, López-Rodríguez M, Ramos JA.

Eur Neuropsychopharmacol. 2006 Jan;16(1):7-18. Epub 2005 Jul 11.

PMID:
16006105
[PubMed - indexed for MEDLINE]
20.

Inhibition of caspase-3-like activity reduces glutamate induced cell death in adult rat retina.

Chen TA, Yang F, Cole GM, Chan SO.

Brain Res. 2001 Jun 15;904(1):177-88.

PMID:
11516428
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk